Reuters logo
BRIEF-Novartis says Phase III trial shows fingolimod reduces relapses in children, adolescents with MS
September 5, 2017 / 5:31 AM / in 3 months

BRIEF-Novartis says Phase III trial shows fingolimod reduces relapses in children, adolescents with MS

Sept 5 (Reuters) - Novartis Ag

* Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS Further company coverage: (Reporting by Zurich Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below